Nektar Therapeutics (NKTR)
El precio, las cifras principales y las últimas noticias, en un solo sitio.
Nektar Therapeutics (NKTR): cotización, análisis y datos
No hay datos disponibles
| Precio de compra | 63.14 |
| Capitalización de mercado | 2.53B |
| Ingresos (TTM) | 54.59M |
| Beneficio neto (TTM) | -157.13M |
| 1.16 | |
| -6.12 | |
| n/a | |
| -6.83 | |
| P/B (TTM) | 2.80 |
| P/S (TTM) | 46.30 |
| Fecha de resultados | Nov 12, 2026 |
| Precio de venta | 84.58 |
| Volumen | 585,337 |
| Volumen medio (20D) | 945,579 |
| Abierto | 75.10 |
| Anterior Cerrar | 74.53 |
| Rango del día | 72.83 - 76.23 |
| Rango de 52 semanas | 26.45 - 109.00 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de NKTR
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 ...
Desempeño financiero
En 2025, los ingresos de Nektar Therapeutics fueron 55.23M, una disminución de -43.89% en comparación con 98.43M del año anterior. Las ganancias fueron -164.08M, un aumento de 37.92%.
Estados financierosSorpresa de resultados
- Ingresos de $10.86M falla las estimaciones por $0, con 3.83% Crecimiento interanual.
- EPS de -1.21 supera las estimaciones en 0.83, con 56.47% Crecimiento interanual.
Los analistas proyectan ingresos de ... Actualizar
1 semana hace · Simply Wall St.
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings SurpriseNektar Therapeutics (NKTR) shares are in focus after the company reported second quarter 2026 results, with revenue of US$10.13 million and a net loss of US$40.62 million, alongside an earnings surpri...
1 semana hace · Simply Wall St.
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial LaunchNektar Therapeutics stock has delivered a very large gain over the past three years, yet the company now screens as expensive on broad valuation checks. After such a strong run, investors are facing a...
1 semana hace · Zacks
Retail Sales Weaken in JulyRetail Sales Weaken in July